Antiphospholipid antibodies and atherosclerosis

Area of Science:

• Immunology
• Cardiovascular Medicine
• Hematology

Background:

• Antiphospholipid antibodies (aPL) are traditionally linked to thrombosis in antiphospholipid syndrome.
• Recent research suggests a role for aPL in atherosclerosis, particularly in myocardial infarction.
• The specificity of aPL may determine their distinct pathogenetic mechanisms and clinical outcomes.

Purpose of the Study:

• To review the diverse roles of antiphospholipid antibodies in thrombosis and atherosclerosis.
• To differentiate the mechanisms and clinical consequences of various aPL specificities.
• To explore the potential role of antibodies to oxidized LDL, beta 2-glycoprotein I, and prothrombin in cardiovascular disease.

Main Methods:

• Review of clinical studies and immunological findings on antiphospholipid antibodies.
• Analysis of the association between specific aPL and thrombotic or atherosclerotic events.
• Discussion of proposed mechanisms for aPL involvement in atherothrombosis.

Main Results:

• Antibodies to oxidized low-density lipoprotein (LDL) are implicated in vascular wall inflammation in atherosclerosis and vasculitis, rather than direct coagulation interference.
• Antibodies to beta 2-glycoprotein I and prothrombin show a stronger association with thrombosis.
• These antibodies may be induced by cryptic epitopes on endothelial-bound proteins within atherosclerotic plaques, promoting a hypercoagulable state.

Conclusions:

• Antiphospholipid antibodies have diverse roles extending beyond traditional thrombosis to include atherosclerosis.
• Specificities of aPL, such as anti-oxidized LDL versus anti-beta 2-glycoprotein I/prothrombin, correlate with different pathogenetic pathways (inflammation vs. coagulation).
• Understanding these specificities is crucial for elucidating the clinical consequences of antiphospholipid antibodies in cardiovascular diseases.